Trial Profile
A Phase III Study Comparing Efficacy and Safety of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Luye Pharma Group
- 07 May 2021 According to a Luye Pharma Group media release, LY01008 (Bevacizumab injection), has received marketing authorization from China's National Medical Products Administration (NMPA), for the treatment of advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC), and metastatic colorectal cancer.
- 20 Apr 2020 According to a Luye Pharma Group media release, marketing authorization application for the LY01008 (Bevacizumab injection), has been accepted by the China Center for Drug Evaluation of National Medical Products Administration. The application was based on clinical data from two comparative studies with Avastin, the first a PK study in healthy subjects, the second a comparative study of efficacy and safety in metastatic or recurrent non-squamous non-small-cell lung cancer patients.
- 04 Nov 2019 According to a Luye Pharma Group media release, the company has completed the observation of the Overall Response Rate (ORR) for the primary endpoint in a blinded state.